The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.

Diğer sürümleri göster (2)

Detaylı Bibliyografya
Asıl Yazarlar:	Clark, W, Jobanputra, P, Barton, P, Burls, A
Materyal Türü:	Journal article
Baskı/Yayın Bilgisi:	2004

Benzer Materyaller

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
Yazar:: Clark, W, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis.
Yazar:: Clark, W, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis
Yazar:: W Clark, ve diğerleri
Baskı/Yayın Bilgisi: (2004-09-01)

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness
Yazar:: Chen, Y, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Yazar:: Chen, Y, ve diğerleri
Baskı/Yayın Bilgisi: (2006)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: A systematic review and economic evaluation
Yazar:: Jobanputra, P, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation.
Yazar:: Jobanputra, P, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation
Yazar:: P. Jobanputra, ve diğerleri
Baskı/Yayın Bilgisi: (2002-01-01)

The trials of anakinra.
Yazar:: Burls, A, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

The safety of interleukin-1 receptor antagonist (anakinra) in the treatment of rheumatoid arthritis
Yazar:: L. Riente
Baskı/Yayın Bilgisi: (2011-09-01)

Hepatotoxicity of tocilizumab and anakinra in rheumatoid arthritis: management decisions
Yazar:: Mahamid M, ve diğerleri
Baskı/Yayın Bilgisi: (2011-10-01)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Yazar:: Ruiz Garcia, V, ve diğerleri
Baskı/Yayın Bilgisi: (2014)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
Yazar:: Barton, P, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.
Yazar:: Barton, P, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis
Yazar:: P Barton, ve diğerleri
Baskı/Yayın Bilgisi: (2004-03-01)

A survey of British rheumatologists' DMARD preferences for rheumatoid arthritis.
Yazar:: Jobanputra, P, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis - Introduction
Yazar:: Barton, P, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.
Yazar:: Ruiz Garcia, V, ve diğerleri
Baskı/Yayın Bilgisi: (2011)

Hepatotoxicity due to tocilizumab and anakinra in rheumatoid arthritis: two case reports
Yazar:: Mahamid M, ve diğerleri
Baskı/Yayın Bilgisi: (2011-09-01)

Severe infection in patients with rheumatoid arthritis taking anakinra, rituximab, or abatacept: a systematic review of observational studies
Yazar:: Vanderlea Poeys Cabral, ve diğerleri

The use of anakinra in a patient with gout and long-term follow-up of rheumatoid arthritis
Yazar:: E. V. Cheremushkina, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

Anakinra, a recombinant human IL-1 receptor antagonist, in clinical practice. Outcome in 60 patients with severe rheumatoid arthritis
Yazar:: S. Todesco, ve diğerleri
Baskı/Yayın Bilgisi: (2011-09-01)

An Economic Comparison of Treatment Strategies with Anakinra in Systemic Juvenile Idiopathic Arthritis (sJIA)
Yazar:: Bullement A, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Etanercept for the treatment of rheumatoid arthritis.
Yazar:: Lethaby, A, ve diğerleri
Baskı/Yayın Bilgisi: (2013)

Infliximab for the treatment of rheumatoid arthritis.
Yazar:: Blumenauer, B, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Etanercept for the treatment of rheumatoid arthritis
Yazar:: Blumenauer, B, ve diğerleri
Baskı/Yayın Bilgisi: (2004)

Etanercept for the treatment of rheumatoid arthritis.
Yazar:: Blumenauer, B, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Problems in the treatment of rheumatoid arthritis and prospects for the use of an IL-1 inhibitor (Anakinra). (Resolution of the Expert Council, May 19, 2022)
Yazar:: article Editorial
Baskı/Yayın Bilgisi: (2022-11-01)

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation
Yazar:: K Malottki, ve diğerleri
Baskı/Yayın Bilgisi: (2011-03-01)

Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation
Yazar:: Y Chen, ve diğerleri
Baskı/Yayın Bilgisi: (2008-04-01)

Anakinra treatment in patients with systemic-onset juvenil idiopathic arthritis: “The Valencia Experience”
Yazar:: Montesinos B, ve diğerleri
Baskı/Yayın Bilgisi: (2011-09-01)

PB2045: USE OF ANAKINRA IN THE TREATMENT OF ADULT HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS: A SYSTEMATIC REVIEW
Yazar:: Ali Eshaghpour, ve diğerleri
Baskı/Yayın Bilgisi: (2023-08-01)

The cost-effectiveness of biologics for the treatment of rheumatoid arthritis: a systematic review.
Yazar:: Jaana T Joensuu, ve diğerleri
Baskı/Yayın Bilgisi: (2015-01-01)

Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation.
Yazar:: Burls, A, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation.
Yazar:: Burls, A, ve diğerleri
Baskı/Yayın Bilgisi: (2002)

Zanamivir for the treatment of influenza in adults: a systematic review and economic evaluation
Yazar:: A. Burls, ve diğerleri
Baskı/Yayın Bilgisi: (2002-01-01)

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.
Yazar:: Clark, W, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease.
Yazar:: Clark, W, ve diğerleri
Baskı/Yayın Bilgisi: (2003)

Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn's disease
Yazar:: W. Clark, ve diğerleri
Baskı/Yayın Bilgisi: (2003-01-01)

Clinical and cost effectiveness of arthritis gloves in rheumatoid arthritis (A-GLOVES): randomised controlled trial with economic analysis
Yazar:: Alison Hammond, ve diğerleri
Baskı/Yayın Bilgisi: (2021-01-01)